Table 1.
Descriptive characteristics of women and men diagnosed with nondistant metastatic colorectal cancer in the Cancer Prevention Study-II by strata of prediagnostic use of aspirin and non-aspirin NSAIDsa
| Characteristic | Aspirin |
Non-aspirin NSAIDS |
||||
|---|---|---|---|---|---|---|
| None | 1 to <15 pills per mo | ≥15 pills per mo | None | 1 to <15 pills per mo | ≥15 pills per mo | |
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |
| Total No. | 1328 | 234 | 1124 | 2056 | 271 | 359 |
| Age at diagnosis, y | ||||||
| <65 | 173 (13.0) | 53 (22.6) | 82 (7.3) | 234 (11.4) | 43 (15.9) | 31 (8.6) |
| 65 to <70 | 272 (20.5) | 44 (18.8) | 192 (17.1) | 388 (18.9) | 49 (18.1) | 71 (19.8) |
| 70 to <75 | 350 (26.4) | 53 (22.6) | 242 (21.5) | 471 (22.9) | 67 (24.7) | 107 (29.8) |
| 75 to <80 | 286 (21.5) | 50 (21.4) | 331 (29.4) | 522 (25.4) | 62 (22.9) | 83 (23.1) |
| 80 to <85 | 163 (12.3) | 26 (11.1) | 188 (16.7) | 297 (14.4) | 34 (12.5) | 46 (12.8) |
| ≥85 | 84 (6.3) | 8 (3.4) | 89 (7.9) | 144 (7.0) | 16 (5.9) | 21 (5.8) |
| Sex | ||||||
| Female | 682 (51.4) | 117 (50.0) | 443 (39.4) | 912 (44.4) | 128 (47.2) | 202 (56.3) |
| Male | 646 (48.6) | 117 (50.0) | 681 (60.6) | 1144 (55.6) | 143 (52.8) | 157 (43.7) |
| Race | ||||||
| White | 1294 (97.4) | 228 (97.4) | 1100 (97.9) | 2004 (97.5) | 265 (97.8) | 353 (98.3) |
| Black | 17 (1.3) | 3 (1.3) | 11 (1.0) | 25 (1.2) | 3 (1.1) | 3 (0.8) |
| Other/Unknown | 17 (1.3) | 3 (1.3) | 13 (1.2) | 27 (1.3) | 3 (1.1) | 3 (0.8) |
| Education | ||||||
| <High school | 86 (6.5) | 17 (7.3) | 68 (6.0) | 137 (6.7) | 19 (7.0) | 15 (4.2) |
| High school graduate | 381 (28.7) | 64 (27.4) | 282 (25.1) | 585 (28.5) | 56 (20.7) | 86 (24.0) |
| Some college | 416 (31.3) | 79 (33.8) | 321 (28.6) | 605 (29.4) | 88 (32.5) | 123 (34.3) |
| College graduate | 438 (33.0) | 73 (31.2) | 449 (39.9) | 720 (35.0) | 107 (39.5) | 133 (37.0) |
| Unknown | 7 (0.5) | 1 (0.4) | 4 (0.4) | 9 (0.4) | 1 (0.4) | 2 (0.6) |
| Stage | ||||||
| Local | 645 (48.6) | 112 (47.9) | 590 (52.5) | 1047 (50.9) | 128 (47.2) | 172 (47.9) |
| Regional | 683 (51.4) | 122 (52.1) | 534 (47.5) | 1009 (49.1) | 143 (52.8) | 187 (52.1) |
| BMI (kg/m2) | ||||||
| <18.5 | 27 (2.0) | 0 (0) | 19 (1.7) | 38 (1.8) | 5 (1.8) | 3 (0.8) |
| 18.5 to <25 | 538 (40.5) | 92 (39.3) | 439 (39.1) | 831 (40.4) | 120 (44.3) | 118 (32.9) |
| 25 to <30 | 501 (37.7) | 98 (41.9) | 460 (40.9) | 823 (40.0) | 89 (32.8) | 147 (40.9) |
| ≥30 | 246 (18.5) | 43 (18.4) | 199 (17.7) | 345 (16.8) | 55 (20.3) | 88 (24.5) |
| Unknown | 16 (1.2) | 1 (0.4) | 7 (0.6) | 19 (0.9) | 2 (0.7) | 3 (0.8) |
| Smoking | ||||||
| Never | 573 (43.1) | 104 (44.4) | 398 (35.4) | 846 (41.1) | 106 (39.1) | 123 (34.3) |
| Current | 85 (6.4) | 13 (5.6) | 40 (3.6) | 111 (5.4) | 10 (3.7) | 17 (4.7) |
| Former | 663 (49.9) | 116 (49.6) | 685 (60.9) | 1092 (53.1) | 154 (56.8) | 218 (60.7) |
| Unknown | 7 (0.5) | 1 (0.4) | 1 (0.1) | 7 (0.3) | 1 (0.4) | 1 (0.3) |
| CVD | 191 (14.4) | 25 (10.7) | 414 (36.8) | 477 (23.2) | 62 (22.9) | 91 (25.3) |
| Diabetes | 162 (12.2) | 23 (9.8) | (20.4) | 334 (16.2) | 33 (12.2) | 47 (13.1) |
| Hypertension | 603 (45.4) | 98 (41.9) | 659 (58.6) | 1034 (50.3) | 126 (46.5) | 200 (55.7) |
| Cholesterol medication | ||||||
| Never | 998 (75.2) | 175 (74.8) | 598 (53.2) | 1380 (67.1) | 172 (63.5) | 219 (61.0) |
| Former | 59 (4.4) | 8 (3.4) | 57 (5.1) | 93 (4.5) | 10 (3.7) | 21 (5.8) |
| Current | 271 (20.4) | 51 (21.8) | 469 (41.7) | 583 (28.4) | 89 (32.8) | 119 (33.1) |
a
Based on status at time of prediagnosis questionnaire. BMI = body mass index; CVD = cardiovascular disease; NSAIDs = non-steroidal anti-inflammatory drugs.